Collectively, our findings suggest that iNOS elicits its oncogenic activity in MpBC by acting on a potent activator of EMT and tumor dedifferentiation (Fig. 7F), providing an additional line of evidence of NOS as a highly valuable molecular target in clinical management of MpBC. This evidence concerns the gene NOS2 and neoplasm.